Table 2.

Impact of BRAF V600E or TERT C228T or Their Coexistence on Clinicopathologic Outcomes of PTC

PTC Type and Clinicopathologic Outcomes	No Mutation			BRAF Mutation Only			P	TERT Mutation Only			P	BRAF + TERT Mutation			P*
	No.	%	No. of Missing Cases	No.	%	No. of Missing Cases		No.	%	No. of Missing Cases		No.	%	No. of Missing Cases
All PTC
Total No. of cases	287			159				26				35
Age at diagnosis, years†	45.3 ± 13.7			44.8 ± 13.5			.724	44.0 ± 14.6			.651	57.4 ± 14.1			< .001
Sex, male	65	22.6		45	28.3		.185	8	30.8		.348	24	68.6		< .001
Tumor size, cm			7			8	.044			2	.885			4	.002
Median	1.7			2.0				1.8				2.7
Interquartile range	1.0-3.0			1.3-3.0				1.1-2.5				1.3-4.0
Multifocality	114	39.7		56	36.6	6	.522	8	32.0	1	.448	12	35.3	1	.617
Extrathyroidal invasion	31	10.8		35	23.0	7	.001	4	16.0	1	.503	23	69.7	2	< .001
Vascular invasion, n (%)	35	12.2	1	28	18.5	8	.074	6	24.0	1	.096	8	27.6	6	.022
Lymph node metastasis	58	20.2		64	42.4	8	< .001	10	38.5		.031	21	63.6	2	< .001
Distant metastatic recurrence	8	2.8		2	1.3		.506	2	7.7		.198	10	28.6		< .001
Disease stage						6
I	219	76.3		106	69.3			18	69.2			8	22.9
II	27	9.4		11	7.2			4	15.4			2	5.7
III	33	11.5		29	18.9			2	7.7			10	28.6
IV	8	2.8		7	4.6		.106	2	7.7		.373	15	42.9		< .001
III+IV	41	14.3		36	23.5		.015	4	15.4		.776	25	71.4		< .001
Tumor recurrence	25	8.7		26	16.3		.015	5	19.2		.081	24	68.6		< .001
Total 131I dose, mCi			5			11	.084			2	.560			5	< .001
Median	74.6			75.4				77				100
Interquartile range	0-100			0-100				0-100				98-136
Total follow-up, months							.048				.030				.864
Median	28			17				66				24
Interquartile range	6-85			3-52				12-116				12-60
CPTC
Total No. of cases	200			136				19				28
Age at diagnosis, years†	46.0 ± 13.7			44.7 ± 12.8			.398	44.2 ± 16.1			.603	56.7 ± 14.2			< .001
Sex, male	47	23.5		41	30.1		.174	6	31.6		.432	19	67.9		< .001
Tumor size, cm			7			8	< .001			2	.349			4	< .001
Median	1.5			2				1.5				2.8
Interquartile range	0.8-2.3			1.3-2.5				1.0-2.3				1.7-3.5
Multifocality	81	40.5		44	33.8	6	.223	6	33.3	1	.552	10	37.0	1	.730
Extrathyroidal invasion	25	12.5		29	22.5	7	.017	4	22.2	1	.272	19	73.1	2	< .001
Vascular invasion	21	10.5	1	23	18.0	8	.055	6	33.3	1	.005	4	18.2	6	.287
Lymph node metastasis	49	24.5		58	45.0	7	< .001	9	47.4		.031	18	69.2	2	< .001
Distant metastatic recurrence	6	3.0		1	0.7		.248	2	10.5		.146	6	21.4		< .001
Disease stage						6
I	159	79.5		92	70.8			13	68.4			6	21.4
II	13	6.5		9	6.9			2	10.5			1	3.6
III	21	10.5		24	18.5			2	10.5			8	28.6
IV	7	3.5		5	3.8		.212	2	10.5		.429	13	46.4		< .001
III+IV	28	14.0		29	22.3		.051	4	21.0		.492	21	75.0		< .001
Tumor recurrence	18	9.0		22	16.2		.046	4	21.0		.107	20	71.4		< .001
Total 131I dose, mCi			3			10	.193			2	.110			5	< .001
Median	50.9			75				100				100
Interquartile range	0-100			0-100				0-103				75-131.5
Total follow-up, months							.025				.067				.686
Median	30.5			17				73				35.5
Interquartile range	8-79			2-48.5				12-108				12-61.5

Abbreviations: CPTC, conventional papillary thyroid cancer; PTC, papillary thyroid cancer.

^*P values are from the comparison of the indicated genetic group in the column immediately left of the P value column with the no mutation group.

^†Data were summarized with means ± standard deviations.